Loading next page...
/lp/elsevier/monocyte-macrophage-system-as-targets-for-immunomodulation-by-19zCrAmnUX
- Publisher
- Elsevier
- Copyright
- Copyright © 2000 Elsevier Ltd
- ISSN
- 0268-960X
- eISSN
- 1532-1681
- DOI
- 10.1054/blre.1999.0121
- Publisher site
- See Article on Publisher Site
Abstract
Pooled human intravenous immunoglobulin (IVIg) has been used successfully to treat or ameliorate the clinical manifestations of humoral immune deficiencies, haematological disorders, HIV infection and many other diseases states. However, the mechanism of action of IVIg remains unclear. Several mechanisms of action of IVIg have been proposed. These include Fcγ receptor blockade, accelerated clearance of endogenous pathogenic auto-antibodies, inhibition of components of the complement cascade, neutralization of super-antigens and bacterial toxins as well as anti-cytokine and anti-idiotype effects. A major contributor to host immunity and immune surveillance against infection, tissue or cell damage and malignancy is the monocyte/macrophage system. Monocyte-directed inflammation is a desirable consequence of microbiological or malignant challenge. However, monocyte hyperactivity may contribute to certain pathological conditions. These include the systemic inflammatory response syndrome (SIRS), septic shock, other dysregulated inflammatory disorders and auto-immunity. Novel therapies that can suppress the hyperactive state or correct monocyte/macrophage dysfunction without compromising normal host cell-mediated immunity are desirable. In this review, we discuss the immunomodulatory effects of IVIg focussing particularly upon the monocyte/macrophage system in pertinent disease states.
Journal
Blood Reviews – Elsevier
Published: Mar 1, 2000
Recommended Articles
Loading...
References
-
Preparations and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibration across membranes with ethanol-water mixtures of controlled pH, ionic strength and temperatureCohn, E.J.; Luetscher, J.A.; Oncley, J.L.; Armstrong, S.H.; Davis, B.D.
-
Preparations and properties of serum and plasma proteins. I. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluidsCohn, E.J.; Strong, L.E.; Hughes, W.L.
-
The gammaglobulins IV. Therapeutic uses of gammaglobulinJaneway, C.A.; Rosen, F.S.
-
Intravenous administration of human gammaglobulinBarandun, S.; Kistler, P.; Jeunet, F.; Isliker, H.
-
Intravenous immunoglobulin (IVIg) in the treatment of autoimmune diseasesKaveri, S.V.; Dietrich, G.; Hurez, V.; Kazatchkine, D.
-
Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralisation by intravenous immunoglobulinLeung, D.Y.M.
-
High dose intravenous IgG in adults with autoimmune thrombocytopeniaNewland, A.C.; Treleaven, J.G.
-
High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhoodImbach, P.; Barandun, S.; d’Apuzzo, V.
-
Clinical benefits and immunopathological correlates of Intravenous Immune Globulin in the treatment of inflammatory myopathiesDalakas, M.C.
-
Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseasesGelfand, E.W.; Landwehr, L.P.; Esterl, B.; Mazer, B.
-
Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infectionOlopoenia, L.; Young, M.; White, D.; Barnes, S.; Rahbar, F.; Fomufod, A.
-
Mechanisms of action of intravenous immune globulin in immune mediated diseasesMouthon, L.; Kaveri, S.V.; Spalter, S.H.; Lacroix-Desmazes, S.; Lefranc, C.; Desai, R.; Kazatchkine, M.D.
-
Manipulating the Immune system with Immune GlobulinDwyer, J.M.
-
High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearanceBasta, M.; Langolis, P.F.; Marques, M.; Frank, M.M.; Fries, L.F.
-
The use and mechanisms of action of intravenous immunoglobulin: an updateNewland, A.C.
-
Modulation of mononuclear phagocyte function by intravenous gamma-globulinKimberly, R.P.; Salmon, J.E.; Bussel, J.B.; Crow, M.K.; Hilgartner, M.W.
-
Mechanisms of action of intravenous immune serum globulin therapyBallow, M.
-
Mechanisms of therapeutic effect of high-dose intravenous immunoglobulin attenuation of acute, complement-dependant immune damage in a guinea pig modelBasta, M.; Kirshbom, P.; Frank, M.M.; Fries, L.F.
-
In vitro inhibition of tumour necrosis factor -α and interleukin – 6 production by intravenous immunoglobulinsToungouz, M.; Denys, C.H.; De Groote, D.; Dupont, E.
-
Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha productionDarville, T.; Milligan, L.B.; Laffoon, K.K.
-
Intravenous Immune Globulin: an alternative therapy in steroid-dependent allergic diseaseGelfand, E.W.; Landwehr, L.P.; Esterl, B.; Mazer, B.
-
Antibody to granulocyte-macrophage colony-stimulaing factor is a dominant anti-cytokine activity in human IgG preparationsSvenson, M.; Hansen, M.B.; Ross, C.
-
Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseasesYu, Z.; Lennon, V.A.
-
Management of septic shockLynn, W.A.; Cohen, J.
-
The potential for monocyte mediated immunotherapy during infection and malignancy. Part 2: In vivo activation by exogenous cytokines and clinical applicationsWilliams, M.A.; Rhoades, C.J.; Newland, A.C.; Kelsey, S.M.
-
The immunotherapeutic potential of the monocyteWilliams, M.A.; Newland, A.C.; Kelsey, S.M.
-
The potential for monocyte mediated immunotherapy during infection and malignancy. Part 1: Apoptosis induction and cytotoxic mechanismsWilliams, M.A.; Newland, A.C.; Kelsey, S.M.
-
Human IgG Fc Receptor Heterogeneity: Molecular Aspects and Clinical ImplicationsVan de Winkel, J.G.J.; Capel, P.J.A.
-
Fc receptors in cancer and infectious diseasesFanger, M.W.; Erbe, D.V.
-
Chronic granulomatous diseaseThrasher, A.J.; Keep, N.H.; Wientses, F.; Segal, A.W.
-
Regulation by differential development of Th1 and Th2 Cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesionIsobe, M.; Suzuki, J.; Yamazaki, S.
-
Synergisitic augmentative effect of interleukin-10 and CD27/CD70 interactions on B-cell immunoglobulin synthesisNagumo, H.; Agematsu, K.
-
CD40 ligand triggers interleukin-6 mediated B cell differentiationUrashima, M.; Chauhan, D.; Hatziyanni, M.
-
Effect of interleukin-10 on anti-CD40- and interleukin-4-induced immunoglobulin E production by human lymphocytesUejima, Y.; Takahashi, K.; Komoriya, K.; Kurozumi, S.; Ochs, H.D.
-
Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytesBurdin, N.; Van Kooten, C.; Galibert, L.
-
The acute phase nature of interleukin 6 studied in kawasaki disease and other febrile illnessUeno, Y.; Takano, N.; Kanegane, H.
-
Granulocyte-macrophage colony-stimulating factor and IFN-γ restore the systemic TNF-α response to endotoxin in lipopolysaccharide-desensitized miceBundschuh, D.S.; Barsig, J.; Hartung, T.; Randow, F.; Döcke, W.; Volk, H.; Wendel, A.
-
Administration of granulocyte-macrophage colony stimulating factor (rHuGM-CSF) after chemotherapy regulates the expression and secretion of monocyte TNF and TNF receptors p55 and p75Williams, M.A.; Kouroumoussis, I.; Syndercombe-Court, D.; Hendry, L.; Newland, A.C.; Kelsey, S.M.
-
Monocyte mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapyWilliams, M.A.; Newland, A.C.; Kelsey, S.M.
-
Direct evidence for Hageman Factor (Factor XII) activation by bacterial lipopolysaccharidesMorrison, D.C.; Cochrane, C.G.
-
Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cellsYao, J.; Mackman, N.; Edington, T.S.; Fan, S.
-
Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythramatosis activityRobak, E.; Sysa-Jedrzejewska, A.; Dziankowska, B.; Torzecka, D.; Chojnowski, K.; Robak, T.
-
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivoAukrust, P.; Frøland, S.S.; Liabakk, N.; Müller, F.; Nordøy, I.; Haug, C.; Espevik, T.
-
Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophagesAnderson, J.; Skansén-Saphir, U.; Sparrelid, E.; Andersson, U.
-
Endocytosis by the mononuclear phagocyte system and autoimmune diseasesKimberly, R.P.; Ralph, P.
-
Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab’) 2 fragmentsRamisse, F.; Deramoudt, F.X.; Szatanik, M.
-
Intravenous immunoglobulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of actionAchiron, A.; Barak, Y.; Goren, M.
-
Down-regulation of cytokine production and interleukin -2 receptor expression by pooled human IgGAndersson, U.G.; Björk, L.; Skansén-Saphir, U.; Andersson, J.P.
-
Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca 2+ dependant signal transduction through Fcγ receptors in B lymphocytesKondo, N.; Kasahara, K.; Kameyama, T.
-
The treatment of kawasaki syndrome with intravenous gamma globulinNewburger, J.W.; Takahashi, M.; Burns, J.C.
-
Immune thrombocytopenia and Fc receptor mediated phagocyte functionNewland, A.C.; Macey, M.G.
-
Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivoAukrust, P.; Müller, F.; Nordøy, I.; Haug, C.J.; Frøland, S.S.
-
Blockade of proliferation and tumor necrosis factor -α production occurring during mixed lymphocyte reaction by interferon-γ-specific natural antibodies contained in intravenous immunoglobulinsToungouz, M.; Denys, C.; Dupont, E.
-
Effects of intravenous immunoglobulins (IVIg) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 moleculesRigal, D.; Vermot-Desroches, C.; Heitz, S.; Bernaud, J.; Alfonsi, F.; Monier, J.C.
-
IVIg adverse reactions: potential role of cytokine and vasoactive substancesBagdasarian, A.; Tonetta, S.; Harel, W.; Mamidi, R.; Uemura, Y.
-
Human intravenous immunoglobulin modulates monokine production in vitroAnderson, J.P.; Andersson, U.G.
-
Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down regulated by pooled human IgGSkansén-Saphir, U.; Andersson, J.; Björk, L.; Andersson, U.
-
Selective induction of IL-1ra and IL-8 in human monocytes by normal polyspecific IG (IVIg)Ruis de Sousa, V.; Carreno, M.; Kaveri, S.V.
-
Immune response associated production of neopterinHuber, C.; Batchelor, J.R.; Fuchs, D.
-
Intravenous Immunoglobulin Induces Interferon-γ and Interleukin-6 in vivoLing, Z.; Yeoh, E.; Webb, B.T.; Farrell, K.; Douchette, J.; Matheson, D.S.
-
Suppression of TNF-α production by human immunoglobulin preparations for intravenous useShimozato, T.; Iwata, M.; Tamura, N.
-
Monocyte-induced down-modulation of CD16 and CD56 antigens on human natural killer cells and its regulation by histamine H2 receptorsHellstrand, K.; Kjellson, B.; Hermodsson, S.
-
Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulinToyoda, M.; Zhang, X.; Petrosian, A.; Galera, O.A.; Wang, S.; Jordan, S.C.
-
Effects by intravenous immunoglobulin in vivo on abnormally increased TNF-α activity in human immunodeficiency virus type 1 infectionAukrust, P.; Hestdal, K.; Lien, E.
-
Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 productionShimozato, T.; Iwata, M.; Kawada, H.; Tamura, N.
-
Regulation of tumor necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMPKatakami, Y.; Nakao, Y.; Koizumi, Y.; Katakami, N.; Ocawa, R.; Fujita, T.
-
Prostaglandins postotranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphateKundsen, P.J.; Dinarello, C.A.; Strom, T.B.
-
Modulation of complement mediated immune damage by intravenous immunoglobulinBasta, M.
-
High dose intravenous immunoglobulin does not affect complement bacteria interactionsWagner, E.; Platt, J.L.; Frank, M.M.
-
Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab’) 2 mediated anti-complement activityLatremouille, C.H.; Genevaz, D.; Hu, M.C.
-
Intravenous Immunoglobulin treatment of experimental colitis induced by dextran sulfate sodium in ratsShintani, N.; Nakajima, T.; Nakakubo, H.
-
High doses of intravenous Ig inhibits in vitro uptake of C4 fragments onto sensitized erythrocytesBasta, M.; Fries, L.F.; Frank, M.M.
-
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal ratJones, E.A.; Waldmann, T.A.
-
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptorJunghans, R.P.; Anderson, C.L.
-
Network theory in autoimmunity: in vitro suppression of serum anti DNA antibody binding to DNA by anti-idiotype antibody in systemic lupus erythematosusAbdou, M.I.; Wall, H.; Lindsley, H.B.; Hasley, J.F.; Sushi, T.
-
Anti-idiotype suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulinSultan, Y.; Maisonneuve, P.; Kazatchkine, M.D.; Nydegger, U.E.
-
Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitroVan Scheik, I.N.; Lunduist, I.; Vermeulen, M.; Brand, A.
-
Correlation of in vitro antibody synthesis with the outcome of intravenous gamma-globulin treatment of chronic idiopathic thrombocytopenic purpuraBussel, J.; Pahwa, S.; Porges, A.
-
Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthaseMacMicking, J.D.; Nathan, C.; Hom, G.
-
Mechanisms of disease: the L-arginine-nitric oxide pathwayMoncada, S.; Higgs, A.
-
Human mononuclear phagocyte inducible nitric oxide synthasse (iNOS): Analysis of iNOS mRNA, iNOS protein, Biopterin and nitric oxide production by blood monocytes and peritoneal macrophagesWeinberg, J.B.; Misukonis, M.A.; Shami, P.J.
-
Nitric oxide regulates interleukin 1 bioactivity released from murine macrophagesHill, J.R.; Corbett, J.A.; Kwon, G.; Marshall, C.A.; McDaniel, M.L.
-
Intravenous Immunoglobulin blocks nitric oxide synthesis and activation induced apoptosis in THP-1 macrophage cellsWilliams, M.A.; Rhoades, C.J.; Lewis, A.; Newland, A.C.; Kelsey, S.M.
-
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulinViard, I.; Wehrli, P.; Bullani, R.
-
Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathwayPrasad, N.K.A.; Papoff, G.
-
Intravenous immunoglobulin induced – nephropathy: a complication of IVIg therapyAhsan, N.
-
New. The use of intravenous immune globulin in Immunodeficiency diseasesBuckley, R.H.; Schiff, R.I.
-
Intravenous immunoglobulin in the treatment of autoimmune diseasesKaveri, S.V.; Dietrich, G.; Hurez, V.; Kazatchkine, M.D.
-
Dermatological uses of high-dose intravenous immunoglobulinJolles, S.; Hughes, J.; Whittaker, S.
-
Current perspectives on the use of IVIgDickler, H.B.; Gelfand, E.W.
-
Supplemental immune globulins in sepsis: a critical appraisalWerdan, K.; Pilz, G.
-
New advances in the therapy for sepsis in childrenAnderson, M.R.; Blumer, J.L.
-
Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsisHaque, K.N.; Remo, C.; Bahakim, H.
-
Effect of neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early onset sepsisChristensen, R.D.; Broun, M.S.; Hall, D.C.; Lassiter, H.A.; Hill, H.R.
-
Intravenous immunoglobulin therapy for toxic shock syndromeBarry, W.; Hudgins, L.; Donta, S.T.; Pesanti, E.L.
-
Effects of intravenous immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritisPap, T.; Reinhold, D.; Kekow, J.
-
Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritisKanik, K.S.; Yarboro, C.H.; Naparstek, Y.; Wilder, R.L.
-
High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritisTumiati, B.; Casoli, P.; Veneziani, M.; Rinaldi, G.
-
Intra-articular administration of polyclonal immunoglobulin G in rheumatoid arthritis. A double-blind, placebo-controlled pilot studyBagge, E.; Geijer, M.; Tarkowski, A.
-
Intravenous immunoglobulins in Still’s disease: still controversial, still unprovenPrieur, A.
-
Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up studyUziel, Y.; Laxer, R.M.; Schneider, R.; Silverman, E.D.
-
High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritisTumiati, B.; Casoli, P.; Veneziani, M.; Rinaldi, G.
-
Infant AIDS prevention study finally gets goingCotton, P.
-
Safety and pharmokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocal 185 Pharmacokinetic Study GroupLambert, J.S.; Mofenson, L.M.; Fletcher, C.V.
-
Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus seropositive donorsCummins, L.M.; Weinhoid, K.J.; Matthews, T.J.
-
Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDSFletcher, C.V.; Goodroad, B.K.; Cummins, L.M.; Henry, K.; Balfour, H.R.; Rhame, F.S.
-
Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseaseTankersley, D.L.
-
Contact activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive propertiesAlving, B.M.; Tankersley, D.L.; Mason, B.L.; Rossi, F.; Aronson, D.L.; Finlayson, J.S.
@Phil_Robichaud
@deepthiw
@JoseServera